This study focuses on patients with advanced cancer for which further treatment is recommended, but standard (“non-research”) treatment is no longer effective. The study will evaluate RGX-104, an investigational drug that binds to proteins. It is hoped that RGX-104 will slow the growth of the patient’s tumor or that the tumor will shrink. Researchers will examine the dosage, safety and side effects of RGX-104, as well as how the drug moves through the body and affects various cells in the blood and cancer.
The study has two parts. The main purpose of Part One is to determine the highest tolerable dose of RGX-104 to be used in Part Two. The second part will assess whether the highest tolerable dose of RGX-104 determined in the first part might be an effective treatment option for people with advanced cancers.
What is the full name of this clinical trial?
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies